Stephen S. Adler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen S. Adler has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Peter L. Choyke
National Cancer Institute, Bethesda, MD, USA
17 shared publications- Cynthia E. Dunbar
Translational Stem Cell Biology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
9 shared publications Jan K. Davidson-Moncada
9 shared publicationsKate Stringaris
9 shared publications- Noriko Sato
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
9 shared publications Richard W. Childs
9 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
Purpose:Glypican-3 (GPC3), which is highly expressed in the most common liver cancer, hepatocellular carcinoma, but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired positron emission tomography (PET) diagnostic and α particle-emitting therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. Experimental Design:Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase–expressing liver cancer models (HepG2 and Hep3B). Microscale co-localization of the radiotheranostic pair was validated using quantitative particle identification spectral autoradiography. A preclinical trial of the therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histologic confirmation, and overall survival (OS). Results:The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200% injected activity per gram) and a high degree of overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses and improved OS compared with control cohorts. We also observed efficacy in the orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. Conclusions:We demonstrate that GPC3-specific PET imaging can predict and assess therapeutic response to GPC3-targeted α particle therapy in orthotopic models of liver cancer. Such an approach can begin to address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
Purpose:Glypican-3 (GPC3), which is highly expressed in the most common liver cancer, hepatocellular carcinoma, but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired positron emission tomography (PET) diagnostic and α particle-emitting therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. Experimental Design:Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase–expressing liver cancer models (HepG2 and Hep3B). Microscale co-localization of the radiotheranostic pair was validated using quantitative particle identification spectral autoradiography. A preclinical trial of the therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histologic confirmation, and overall survival (OS). Results:The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200% injected activity per gram) and a high degree of overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses and improved OS compared with control cohorts. We also observed efficacy in the orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. Conclusions:We demonstrate that GPC3-specific PET imaging can predict and assess therapeutic response to GPC3-targeted α particle therapy in orthotopic models of liver cancer. Such an approach can begin to address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
- 9 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32  (22) , 5100-5113
Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
Purpose: Glypican-3 (GPC3), which is highly expressed in the most common liver cancer, hepatocellular carcinoma, but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired positron emission tomography (PET) diagnostic and α particle-emitting therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. Experimental Design: Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase–expressing liver cancer models (HepG2 and Hep3B). Microscale co-localization of the radiotheranostic pair was validated using quantitative particle identification spectral autoradiography. A preclinical trial of the therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histologic confirmation, and overall survival (OS). Results: The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200% injected activity per gram) and a high degree of overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses and improved OS compared with control cohorts. We also observed efficacy in the orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. Conclusions: We demonstrate that GPC3-specific PET imaging can predict and assess therapeutic response to GPC3-targeted α particle therapy in orthotopic models of liver cancer. Such an approach can begin to address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.
- 9 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32  (22) , 5100-5113
Glypican-3–Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
Purpose: Glypican-3 (GPC3), which is highly expressed in the most common liver cancer, hepatocellular carcinoma, but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired positron emission tomography (PET) diagnostic and α particle-emitting therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. Experimental Design: Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase–expressing liver cancer models (HepG2 and Hep3B). Microscale co-localization of the radiotheranostic pair was validated using quantitative particle identification spectral autoradiography. A preclinical trial of the therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histologic confirmation, and overall survival (OS). Results: The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200% injected activity per gram) and a high degree of overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses and improved OS compared with control cohorts. We also observed efficacy in the orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. Conclusions: We demonstrate that GPC3-specific PET imaging can predict and assess therapeutic response to GPC3-targeted α particle therapy in orthotopic models of liver cancer. Such an approach can begin to address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.
- Open Access
- 8 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-13
Centrifuge-free cell radiolabeling using acoustophoresis
Tracking ex vivo radiolabeled cells using radionuclide imaging such as positron emission tomography is an emerging method for evaluating cell-based therapies. Traditional radiolabeling requires a centrifuge in multiple steps to optimize labeling and remove unbound radiotracers. With the goal of automating the radiolabeling procedure, we explored an acoustophoresis-based approach for radiolabeling cells, eliminating the need of using a centrifuge, simplifying the design of this future device. The AcouWash 2 (AcouSort AB, Lund, Sweden), an acoustophoresis based cell washing device, was evaluated for its ability to label EL4 murine T lymphoblasts with zirconium-89 (89Zr)-oxine without centrifugation. The AcouWash 2 successfully replaced the culture medium with a protein-free buffer, as required for 89Zr-oxine cell labeling. Additionally, it was able to concentrate EL4 cells by a factor of 5.6 ± 0.4, achieving or exceeding the optimal labeling cell density. After cell incubation with 89Zr-oxine, AcouWash 2 exchanged the incubation solution with a solution for infusion, removing unbound 89Zr-oxine. These steps eliminated the need for centrifugation at each stage of the labeling procedure. The resulting radiolabeled EL4 cells exhibited labeling metrics, specific activity, percent labeling efficiency, percent free 89Zr-oxine in the suspension buffer and cell viability, comparable to those obtained from conventional centrifuge-based method. Our results demonstrate that the radiolabeling can be performed entirely using acoustophoresis, which paves the way for developing a fully automated radiolabeling device based on acoustophoresis technology.
- 8 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-13
Open AccessCentrifuge-free cell radiolabeling using acoustophoresis
Tracking ex vivo radiolabeled cells using radionuclide imaging such as positron emission tomography is an emerging method for evaluating cell-based therapies. Traditional radiolabeling requires a centrifuge in multiple steps to optimize labeling and remove unbound radiotracers. With the goal of automating the radiolabeling procedure, we explored an acoustophoresis-based approach for radiolabeling cells, eliminating the need of using a centrifuge, simplifying the design of this future device. The AcouWash 2 (AcouSort AB, Lund, Sweden), an acoustophoresis based cell washing device, was evaluated for its ability to label EL4 murine T lymphoblasts with zirconium-89 (89Zr)-oxine without centrifugation. The AcouWash 2 successfully replaced the culture medium with a protein-free buffer, as required for 89Zr-oxine cell labeling. Additionally, it was able to concentrate EL4 cells by a factor of 5.6 ± 0.4, achieving or exceeding the optimal labeling cell density. After cell incubation with 89Zr-oxine, AcouWash 2 exchanged the incubation solution with a solution for infusion, removing unbound 89Zr-oxine. These steps eliminated the need for centrifugation at each stage of the labeling procedure. The resulting radiolabeled EL4 cells exhibited labeling metrics, specific activity, percent labeling efficiency, percent free 89Zr-oxine in the suspension buffer and cell viability, comparable to those obtained from conventional centrifuge-based method. Our results demonstrate that the radiolabeling can be performed entirely using acoustophoresis, which paves the way for developing a fully automated radiolabeling device based on acoustophoresis technology.
- Open Access
- 15 May 2025
- Published by Springer Nature in Communications Engineering
- Vol. 4  (1) , 89
A Quantitative Particle Identification (QPID) spectral autoradiography system
Autoradiography is used to study the distribution and binding of radioisotope tagged ligands in tissue at microscale among other applications. The technology has evolved since its inception when it used analogue film exposure techniques with the introduction of digital imaging systems sensitive to ionizing radiation. We report on the development of our Quantitative Particle Identification spectral autoradiography system (QPID), which is based on the Timepix3 sensor and a gamma detecting scintillation crystal. This autoradiography system leverages the ionizing radiation detection features of the Timepix3 to measure the energy deposition from charged particles from radioisotopes with a time resolution of 7.7 ns full width at half max (FWHM), generating spectral or activity autoradiography images. The QPID includes a scintillation crystal used to record gamma emissions coincident with the Timepix3 ionization events with a time resolution of 24.2 ns FWHM. The QPID can separate tracks between α and ß particles, select specific ranges of deposited energies or select on the presence of coincident gamma emissions within a selected energy range when generating images. The QPID has a 10% linearity response up to 700 Bq for 223Ra and 2.5 kBq for 18 F radioisotopes. Using α and ß+ particle identification filters, separate images of 223RaCl2 and Na18F activity distributions were generated from a bone sample infused with the two radioligands together. This unique capability can open the door to the study of targeted radiotherapies which use theranostic α and ß+ imaging agents by measuring their relative pharmacokinetic properties.
- 15 May 2025
- Published by Springer Nature in Communications Engineering
- Vol. 4  (1) , 89
Open AccessA Quantitative Particle Identification (QPID) spectral autoradiography system
Autoradiography is used to study the distribution and binding of radioisotope tagged ligands in tissue at microscale among other applications. The technology has evolved since its inception when it used analogue film exposure techniques with the introduction of digital imaging systems sensitive to ionizing radiation. We report on the development of our Quantitative Particle Identification spectral autoradiography system (QPID), which is based on the Timepix3 sensor and a gamma detecting scintillation crystal. This autoradiography system leverages the ionizing radiation detection features of the Timepix3 to measure the energy deposition from charged particles from radioisotopes with a time resolution of 7.7 ns full width at half max (FWHM), generating spectral or activity autoradiography images. The QPID includes a scintillation crystal used to record gamma emissions coincident with the Timepix3 ionization events with a time resolution of 24.2 ns FWHM. The QPID can separate tracks between α and ß particles, select specific ranges of deposited energies or select on the presence of coincident gamma emissions within a selected energy range when generating images. The QPID has a 10% linearity response up to 700 Bq for 223Ra and 2.5 kBq for 18 F radioisotopes. Using α and ß+ particle identification filters, separate images of 223RaCl2 and Na18F activity distributions were generated from a bone sample infused with the two radioligands together. This unique capability can open the door to the study of targeted radiotherapies which use theranostic α and ß+ imaging agents by measuring their relative pharmacokinetic properties.
- 14 May 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31  (14) , 2847-2849
Size Matters: Superior Efficacy of α Particle Radioimmunotherapy in Micrometastases versus Macrometastases
Summary: Radiopharmaceuticals, which emit either α or β particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted α particle–emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus macrometastatic disease. See related article by Bidkar et al., p. 2963
- 14 May 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31  (14) , 2847-2849
Size Matters: Superior Efficacy of α Particle Radioimmunotherapy in Micrometastases versus Macrometastases
Summary: Radiopharmaceuticals, which emit either α or β particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted α particle–emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus macrometastatic disease. See related article by Bidkar et al., p. 2963
- Open Access
Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer
Advanced prostate cancer is treated with androgen receptor (AR) signaling inhibitors, which are initially effective, but most patients eventually develop resistance and progress to castrate-resistant prostate cancer (CRPC). Loss of RB1 in CRPC tumors is correlated with rapid progression and poor patient survival and, in combination with TP53 loss, predisposes patients to the development of transitional neuroendocrine prostate cancer (NEPC). Although progressive CRPC is clinically associated with higher 18FDG-PET SUVmax values, it is unknown whether inactivation of RB1 and/or TP53 is a driver of increased glucose import. Using a cohort of patient-derived xenograft (PDX)-derived CRPC organoids, we found that NEPC could not be conclusively distinguished from adenocarcinoma by 18FDG uptake alone, and PSMA protein levels did not correlate with cancer phenotype or 18FDG uptake. Castration-resistant models showed higher 18FDG uptake, but lower pyruvate-to-lactate conversion compared to their castration-sensitive counterparts. In parallel studies using castration-sensitive prostate cancer models, RB1/TP53 knockdown did not affect 18FDG uptake, but increased basal respiration and glycolytic activity, with combined depletion leading to glucose diversion into glycogenesis. These metabolic changes were reflected in increased lactate dehydrogenase flux detected by 13C-hyperpolarized magnetic resonance spectroscopy upon RB1 loss, but not in 18FDG uptake. The metabolic heterogeneity revealed here suggests that a multimodal molecular imaging approach can improve tumor characterization, potentially leading to a better prognosis in cancer treatment.
Open AccessMetabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer
Advanced prostate cancer is treated with androgen receptor (AR) signaling inhibitors, which are initially effective, but most patients eventually develop resistance and progress to castrate-resistant prostate cancer (CRPC). Loss of RB1 in CRPC tumors is correlated with rapid progression and poor patient survival and, in combination with TP53 loss, predisposes patients to the development of transitional neuroendocrine prostate cancer (NEPC). Although progressive CRPC is clinically associated with higher 18FDG-PET SUVmax values, it is unknown whether inactivation of RB1 and/or TP53 is a driver of increased glucose import. Using a cohort of patient-derived xenograft (PDX)-derived CRPC organoids, we found that NEPC could not be conclusively distinguished from adenocarcinoma by 18FDG uptake alone, and PSMA protein levels did not correlate with cancer phenotype or 18FDG uptake. Castration-resistant models showed higher 18FDG uptake, but lower pyruvate-to-lactate conversion compared to their castration-sensitive counterparts. In parallel studies using castration-sensitive prostate cancer models, RB1/TP53 knockdown did not affect 18FDG uptake, but increased basal respiration and glycolytic activity, with combined depletion leading to glucose diversion into glycogenesis. These metabolic changes were reflected in increased lactate dehydrogenase flux detected by 13C-hyperpolarized magnetic resonance spectroscopy upon RB1 loss, but not in 18FDG uptake. The metabolic heterogeneity revealed here suggests that a multimodal molecular imaging approach can improve tumor characterization, potentially leading to a better prognosis in cancer treatment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma
Molecular imaging approaches for metabolic and physiologic imaging of tumors have become important for treatment planning and response monitoring. However, the relationship between the physiologic and metabolic aspects of tumors is not fully understood. Here, we developed new hyperpolarized MRI and electron paramagnetic resonance imaging procedures that allow more direct assessment of tumor glycolysis and oxygenation status quantitatively. We investigated the spatial relationship between hypoxia, glucose uptake, and glycolysis in three human pancreatic ductal adenocarcinoma tumor xenografts with differing physiologic and metabolic characteristics. At the bulk tumor level, there was a strong positive correlation between 18F-FDG-PET and lactate production, while pO2 was inversely related to lactate production and 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake. However, metabolism was not uniform throughout the tumors, and the whole tumor results masked different localizations that became apparent while imaging. 18F-FDG uptake negatively correlated with pO2 in the center of the tumor and positively correlated with pO2 on the periphery. In contrast to pO2 and 18F-FDG uptake, lactate dehydrogenase activity was distributed relatively evenly throughout the tumor. The heterogeneity revealed by each measure suggests a multimodal molecular imaging approach can improve tumor characterization, potentially leading to better prognostics in cancer treatment.Significance:Novel multimodal molecular imaging techniques reveal the potential of three interrelated imaging biomarkers to profile the tumor microenvironment and interrelationships of hypoxia, glucose uptake, and glycolysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma
Molecular imaging approaches for metabolic and physiologic imaging of tumors have become important for treatment planning and response monitoring. However, the relationship between the physiologic and metabolic aspects of tumors is not fully understood. Here, we developed new hyperpolarized MRI and electron paramagnetic resonance imaging procedures that allow more direct assessment of tumor glycolysis and oxygenation status quantitatively. We investigated the spatial relationship between hypoxia, glucose uptake, and glycolysis in three human pancreatic ductal adenocarcinoma tumor xenografts with differing physiologic and metabolic characteristics. At the bulk tumor level, there was a strong positive correlation between 18F-FDG-PET and lactate production, while pO2 was inversely related to lactate production and 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake. However, metabolism was not uniform throughout the tumors, and the whole tumor results masked different localizations that became apparent while imaging. 18F-FDG uptake negatively correlated with pO2 in the center of the tumor and positively correlated with pO2 on the periphery. In contrast to pO2 and 18F-FDG uptake, lactate dehydrogenase activity was distributed relatively evenly throughout the tumor. The heterogeneity revealed by each measure suggests a multimodal molecular imaging approach can improve tumor characterization, potentially leading to better prognostics in cancer treatment.Significance:Novel multimodal molecular imaging techniques reveal the potential of three interrelated imaging biomarkers to profile the tumor microenvironment and interrelationships of hypoxia, glucose uptake, and glycolysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma
Complete and detailed descriptions of materials and methods are in the supplementary information, including animal studies, image registration, hyperpolarized 13C MRI, 18F-FDG PET, EPR imaging, Western blot, Immunohistochemistry, and statistical analysis. A supplementary Figure S contains H&E and CD31 staining of 100 μm thick slices from the center of the xenograft tumors to depict differences in vascularity are not the primer driver for the rim/interior difference in FDG uptake and O2 levels.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma
Complete and detailed descriptions of materials and methods are in the supplementary information, including animal studies, image registration, hyperpolarized 13C MRI, 18F-FDG PET, EPR imaging, Western blot, Immunohistochemistry, and statistical analysis. A supplementary Figure S contains H&E and CD31 staining of 100 μm thick slices from the center of the xenograft tumors to depict differences in vascularity are not the primer driver for the rim/interior difference in FDG uptake and O2 levels.